A Multi-mRNA Prognostic Signature for Anti-TNFα Therapy Response in Patients with Inflammatory Bowel Disease.

ABSTRACT:

Background

Anti-TNF-alpha (anti-TNFα) therapies have transformed the care and management of inflammatory bowel disease (IBD). However, they are expensive and ineffective in greater than 50% of patients, and they increase the risk of infections, liver issues, arthritis, and lymphoma. With 1.6 million Americans suffering from IBD and global prevalence on the rise, there is a critical unmet need in the use of anti-TNFα therapies: a test for the likelihood of therapy response. Here, as a proof-of-concept, we present a multi-mRNA signature for predicting response to anti-TNFα treatment to improve the efficacy and cost-to-benefit ratio of these biologics.

Methods

We surveyed public data repositories and curated four transcriptomic datasets (n = 136) from colonic and ileal m

SUBMITTER: Sakaram S 

PROVIDER: S-EPMC8534494 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature